Breaking News Instant updates and real-time market news.

JD

JD.com

$42.19

-0.08 (-0.19%)

, TWX

Time Warner

$92.38

-0.57 (-0.61%)

07:35
12/26/17
12/26
07:35
12/26/17
07:35

Unusual call flow in option market yesterday

Notable call activity was cited Friday in JD.com (JD), Time Warner (TWX), Nucor (NUE), NRG Energy (NRG), Viacom (VIAB), Weight Watchers (WTW), Exelixis (EXEL), AES Corp. (AES), and Party City (PRTY).

JD

JD.com

$42.19

-0.08 (-0.19%)

TWX

Time Warner

$92.38

-0.57 (-0.61%)

NUE

Nucor

$64.56

0.03 (0.05%)

NRG

NRG Energy

$28.16

0.7 (2.55%)

VIAB

Viacom

$32.23

0.47 (1.48%)

WTW

Weight Watchers

$50.52

3.07 (6.47%)

EXEL

Exelixis

$29.47

1.66 (5.97%)

AES

AES Corp.

$10.71

0.09 (0.85%)

PRTY

Party City

$13.95

1.75 (14.34%)

  • 08

    Jan

  • 18

    Jan

  • 08

    Feb

  • 15

    Feb

JD JD.com
$42.19

-0.08 (-0.19%)

12/13/17
STFL
12/13/17
INITIATION
Target $48
STFL
Buy
JD.com resumed with a Buy at Stifel
Stifel analyst Scott Devitt resumed coverage of JD.com (JD) with a Buy rating and a $48 price target, saying he views the company and Alibaba (BABA) as well-managed and well-positioned leaders in China that "have effectively shut Amazon out" of the e-commerce market in the region. Devitt predicts JD should triple its 2013 market share to about 18% share by year-end and that third-party can exceed 50% of JD's gross merchandise volume within the next several years.
11/28/17
BERN
11/28/17
NO CHANGE
BERN
Grocery sales on Alibaba, JD.com are nine times Amazon's, says Bernstein
Bernstein analyst Bruno Monteyne notes that absolute grocery sales on Alibaba (BABA) and JD.com (JD) are nine times the grocery sales on Amazon.com (AMZN). China's speed is explained by a lack of legacy, as the country never developed big-box retailing, he adds. Further, Monteyne points out that Alibaba's approach has led to an asset light form of e-grocery, contrasting with the very asset-heavy approach taken by Amazon.
11/14/17
11/14/17
DOWNGRADE
Target $45

Equal Weight
JD.com downgraded to Equal Weight with pause in rally expected at Morgan Stanley
As previously reported, Morgan Stanley analyst Grace Chen downgraded JD.com to Equal Weight from Overweight following the stock's 63% year-to-date advance, as she believes headwinds from the apparel segment may temper gross merchandise value growth in the next few quarters and prompt a "breather" in the stock's rally. While she remains positive on JD's long-term growth potential, she recommends investors wait for a better entry point. Chen lowered her price target on JD shares to $45 from $53.
11/14/17
MSCO
11/14/17
DOWNGRADE
MSCO
Equal Weight
JD.com downgraded to Equal Weight from Overweight at Morgan Stanley
TWX Time Warner
$92.38

-0.57 (-0.61%)

12/04/17
JEFF
12/04/17
NO CHANGE
Target $194
JEFF
Hold
Jefferies sees Aetna trading at 10% discount to deal price
Jefferies analyst David Windley sees Aetna (AET) trading at a 10% spread to the $207 per share price paid by CVS Health (CVS) given the deal's "regulatory hurdles." The analyst sees Aetna trading today to $186 per share. Aetna in premarket trading is up 3%, or $5.99, to $187.30. Windley raised his price target for the stock to $194 from $185 and keeps a Hold rating on the name. The Department of Justice's stance on another major vertical integration, AT&T's (T) acquisition of Time Warner (TWX), suggests the CVS, Aetna transaction could face "significant scrutiny," Windley tells investors in a research note. He believes the regulatory cycle will likely take 9-12 months and may require some Part D divestitures.
11/29/17
KEYB
11/29/17
NO CHANGE
KEYB
Q3 results, analysis of Q4 viewership trends show some bright spots, says KeyBanc
KeyBanc analyst Andy Hargreaves notes that the Department of Justice's decision to sue to block AT&T (T)/Time Warner (TWX) seems likely to halt additional M&A until a resolution is reached. Additionally, the analyst points out that Q4 viewership trends appear most positive for Discovery (DISCA), Viacom (VIAB) so far, and 21st Century Fox (FOXA) remains his favorite long among TV network stocks.
11/21/17
BARD
11/21/17
NO CHANGE
Target $42
BARD
Outperform
Merits of antitrust case favor AT&T, says Baird
Baird analyst William Power noted the DOJ sued to block the AT&T (T) and Time Warner (TWX) deal largely on the grounds that the merger would harm consumers due to higher content prices. The analyst finds it difficult to believe that, given other competition, the company would be able to significantly raise pricing for Turner properties or HBO and risk driving away current partners. He said although his thesis is at risk from the suit, he ultimately believes the merits of the case favor AT&T. Power reiterated his Outperform rating and $42 price target on AT&T shares.
11/21/17
NOMU
11/21/17
NO CHANGE
Target $42
NOMU
Buy
AT&T price target lowered to $42 from $45 at Nomura Instinet
Nomura Instinet analyst Jeffrey Kvaal lowered his price for AT&T (T) shares target to $42 after the Justice Department filed a lawsuit to block the company's acquisition of Time Warner (TWX). The analyst notes he didn't lowered his target post the Q3 video miss given the pending deal. He believes the shares have "room to run" with or without Time Warner and keeps a Buy rating on AT&T.
NUE Nucor
$64.56

0.03 (0.05%)

12/20/17
12/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. United Continental (UAL) upgraded to Buy from Neutral at Buckingham with the firm citing the active steps the company is taking to address revenue weakness, its commercial initiatives, a favorable macro backdrop that is driving booking strength, and the longer term cash implications of tax reform. 2. Wendy's (WEN) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan citing "solid" same-store sales growth and visibility into free cash flow generation. 3. Biogen (BIIB) upgraded to Outperform from Neutral at Credit Suisse with analyst Alethia Young saying a "significant turnaround" is underway for Biogen's business. 4. Steel Dynamics (STLD) was upgraded to Buy from Neutral at Longbow while, U.S. Steel (X), AK Steel (AKS), and Nucor (NUE) were upgraded to Buy from Neutral. 5. Zimmer Biomet (ZBH) upgraded to Neutral from Sell at Goldman Sachs with analyst Isaac Ro saying he sees Bryan Hanson's CEO appointment as a positive step forward in the turnaround process, although he noted that the company's fundamentals are still challenged and the turnaround will take time. Shares were also upgraded to Outperform from Market Perform at Wells Fargo. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
LBOW
12/20/17
UPGRADE
Target $72
LBOW
Buy
Nucor upgraded to Buy on positive survey results at Longbow
As previously reported, Longbow upgraded Nucor to Buy from Neutral with a $72 price target. Analyst Chris Olin's latest carbon steel survey work suggests domestic producers are positioned to realize impressive earnings growth over the next 12-18 months on much higher flat rolled pricing, favorable automotive/annual contract rollovers, and pending tax reform. Olin raised his 2018 HRC price forecast by $45-$50/ton to $660-$670/ton and sees further upside should the DOC release a positive Section-232 recommendation in mid-January.
12/20/17
LBOW
12/20/17
UPGRADE
LBOW
Buy
Nucor upgraded to Buy from Neutral at Longbow
12/21/17
MSCO
12/21/17
NO CHANGE
MSCO
Equal Weight
Cleveland-Cliffs a key beneficiary of corporate AMT repeal, says Morgan Stanley
Morgan Stanley analyst Piyush Sood noted that Steel Dynamics (STLD) and Nucor (NUE) have been the "preferred tax reform plays" in the steel sector, but he believes that Cleveland-Cliffs (CLF), as well as Warrior Met Coal (HCC) and Freeport McMoran (FCX), should benefit from the corporate alternative minimum tax repeal, as they all carry substantial AMT credits on their balance sheets. He keeps Equal Weight ratings on Cleveland, Warrior and Freeport.
NRG NRG Energy
$28.16

0.7 (2.55%)

08/16/17
DBAB
08/16/17
NO CHANGE
Target $38
DBAB
Buy
NRG Energy shares have 50% more upside, says Deutsche Bank
Deutsche Bank analyst Abe Azar raised his price target for NRG Energy shares to $38 from $27 to reflect the company's planned transformation. Even with the rally year-to-date, NRG is still trading at an "unwarranted significant discount to peers," Azar tells investors in a research note titled "Baby, we were born to run." The analyst believes the stock has an additional 50% upside and reiterates a Buy rating on the name. Asset sales throughout the year and an investor day early next year set up a "favorable catalyst calendar and should lead to the stock to re-rate higher," Azar writes.
07/13/17
LEHM
07/13/17
NO CHANGE
Target $27
LEHM
Overweight
NRG Energy price target raised to $27 from $20 at Barclays
Barclays analyst Daniel Ford raised his price target for NRG Energy to $27 saying the company's transformation plan is "significantly accretive." NRG's plan to sell between a 50%-100% stake in NRG Yield and Renewables, plus 6GWs of conventional generation can achieve management's projected $2.0B-$4.5B in cash proceeds and reduction of $8.7B in debt, Ford tells investors in a research note. His upside case has $11 per share of valuation accretion to $38 per share. The analyst reiterates an Overweight rating on the shares.
06/01/17
UBSW
06/01/17
UPGRADE
Target $20
UBSW
Buy
NRG Energy upgraded to Buy from Neutral at UBS
UBS analyst Julien Dumoulin-Smith upgraded NRG Energy to Buy and raised his price target for the shares to $20 from $19. The proposed GenOn settlement is a positive and, along with the latest PJM auction, adds "clarity to the story," Dumoulin-Smith tell investors in a research note. He also views the NRG's cost cutting initiative as the major near-term catalyst for the shares.
05/24/17
FBCO
05/24/17
NO CHANGE
FBCO
Outperform
Exelon a net winner despite 'disappointing' 2020/21 auction, says Credit Suisse
Following PJM Interconnection's annual capacity auction, Credit Suisse analyst Michael Weinstein called Exelon a net winner despite "disappointing" RPM results for the 2020/21 capacity auction. The results for the EMAAC area should help drive a net positive result for Exelon assuming the same amount of capacity cleared year-over-year, he indicated. PSEG (PEG) and Calpine (CPN)are also "net beneficiaries," while Dynegy (DYN), NRG Energy (NRG) and FirstEnergy (FE) will "bear the brunt of a poor RTO showing," Weinstein tells investors.
VIAB Viacom
$32.23

0.47 (1.48%)

11/20/17
11/20/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Verizon (VZ) upgraded to Outperform from Market Perform at Wells Fargo with analyst Jennifer Fritzsche saying after dropping 16% since mid-January, "much of the bad news is behind the stock" in terms of wireless service revenue declines. 2. 3D Systems (DDD) upgraded to Neutral from Underweight at Piper Jaffray with analyst Troy Jensen saying he sees limited downside from current share levels. 3. Viacom (VIAB, VIA) upgraded to Hold from Sell at Deutsche Bank with analyst Bryan Kraft saying he sees limited room for further multiple compression. 4. Maxwell (MXWL) upgraded to Buy from Neutral at Roth Capital with analyst Craig Irwin saying he sees consensus estimates as achievable for 2018, and merger synergies with NessCap should start making a more material contribution over the next few quarters. 5. National Beverage (FIZZ) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic citing his increased conviction on the sales and bottom-line upside of the company. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/20/17
DBAB
11/20/17
UPGRADE
Target $25
DBAB
Hold
Viacom upgraded to Hold from Sell at Deutsche Bank
Deutsche Bank analyst Bryan Kraft upgraded Viacom to Hold saying he sees limited room for further multiple compression. The analyst believes reports of merger speculation in the media space should provide valuation support and he keeps a $25 price target for Viacom shares.
11/17/17
RBCM
11/17/17
NO CHANGE
Target $23
RBCM
Underperform
Viacom price target lowered to $23 from $30 at RBC Capital
RBC Capital analyst Steven Cahall lowered his price target on Viacom to $23 following Q4 results. Cahall says that despite the EPS beat, weaker domestic affiliate revenue growth was the latest surprising development as part of a trend of negative estimate revisions. The analyst keeps his Underperform rating, saying that investors are cautious on exposure to Media amid a "gravitational pull toward more visible growth stories", particularly as Viacom undergoes a period of strategic restructuring.
WTW Weight Watchers
$50.52

3.07 (6.47%)

11/07/17
CHLM
11/07/17
NO CHANGE
Target $70
CHLM
Buy
Weight Watchers price target raised to $70 from $50 at Craig-Hallum
Craig-Hallum analyst Alex Fuhrman raised his price target for Weight Watchers to $70 from $50 after the company delivered a "strong" beat and raise as retention reaches multi-year highs. The analyst believes momentum is building in 2017 with potential for significant upside to estimates in 2018. Fuhrman reiterates a Buy rating on the shares.
12/20/17
12/20/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with a Buy at B. Riley FBR. 2. Cloudera (CLDR) initiated with a Buy at Drexel Hamilton. 3. Trade Desk (TTD) initiated with an Outperform at Wells Fargo. 4. RGC Resources (RGCO) initiated with a Neutral at Janney Capital. 5. Extreme Networks (EXTR) initiated with an Outperform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/20/17
RILY
12/20/17
INITIATION
Target $65
RILY
Buy
Weight Watchers initiated with a Buy at B. Riley FBR
B. Riley FBR started Weight Watchers with a Buy rating and $65 price target.
12/20/17
RILY
12/20/17
NO CHANGE
Target $65
RILY
Buy
B. Riley FBR starts Weight Watchers with Buy rating, $65 target
B. Riley FBR analyst Kara Anderson initiated last night shares of Weight Watchers with a Buy rating and $65 price target. The analyst sees multiple long-term growth levers that could drive the company's sales back to peak levels in five years. In the near-term, Anderson expects solid recruitment from Weight Watchers' new plan launching for the 2018 diet season.
EXEL Exelixis
$29.47

1.66 (5.97%)

09/22/17
RHCO
09/22/17
NO CHANGE
RHCO
Exelixis trial likely to be continued, says SunTrust
SunTrust analyst Peter Lawson says that the trial of Exelixis' cabozantinib.in liver cancer will most likely be continued through 2018. He views this scenario as "neutral to negative" for the stock. However, he recommends buying the shares on any weakness, citing what he sees as upcoming positive catalysts, including opportunities in bladder, breast and lung, new data, "and potential revenue beats from broadening use and 1H18 label expansion." He keeps a $33 price target and a Buy rating on the shares.
10/16/17
RHCO
10/16/17
NO CHANGE
Target $35
RHCO
Buy
Cabo result better positions Exelixis as acquisition target, says SunTrust
SunTrust analyst Peter Lawson raised his price target on Exelixis (EXEL) to $35 from $33 and maintained his Buy rating, saying the latest CELESTIAL trial cabozantinib positions the treatment well against its main competitor - Bayer's (BAYRY) Regorafenib. Lawson adds that the trial result validates the expansion of cabozantinib beyond kidney cancer and better positions Exelixis as a potentially attractive M&A target.
10/16/17
PIPR
10/16/17
NO CHANGE
Target $33
PIPR
Overweight
Exelixis price target raised to $33 from $29 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Exelixis shares to $33 after the company said the Phase III Celestial trial of Cabometyx met the primary endpoint. The analyst is confident front-line approval next year will grow renal cell carcinoma product sales to $392M in 2018. He reiterates an Overweight rating on Exelixis.
10/17/17
NEED
10/17/17
NO CHANGE
Target $33
NEED
Buy
Exelixis price target raised to $33 from $30 at Needham
Needham analyst Chad Messer raised his price target on Exelixis (EXEL) to $33, noting the latest trial data for advanced renal cell carcinoma treatment, Cabozantinib, positions it for near and long term growth. Messer says the results may be sufficient to allay competitive concerns from the recently approved Bayer (BAYRY) Stivarga, as cabozantinib offers a potentially more attractive efficacy profile.
AES AES Corp.
$10.71

0.09 (0.85%)

11/13/17
BOFA
11/13/17
UPGRADE
Target $12
BOFA
Buy
AES Corp. upgraded to Buy from Neutral at BofA/Merrill
BofA/Merrill analyst Julien Dumoulin-Smith upgraded AES to Buy and raised its price target to $12 from $11.50 saying the recent selloff in shares is "unwarranted" given potential asset sales, cost cuts, and a robust high-yield backdrop.
09/13/17
RHCO
09/13/17
NO CHANGE
RHCO
Multiple catalysts could help AES Corp. stock, says SunTrust
SunTrust analyst Ali Agha believes that multiple, positive catalysts over the next three months "should bode well" for the performance of AES Corp stock. The analyst believes that a pending decision by Ohio regulators will increase the company's annual EPS by 11c, and he thinks an announcement of a sale of its remaining 51% stake in its Phillippines assets would also help the stock. Finally, he believes that by listing its Eletropaulo subsidiary on the Brazilian stock exchange, the company will be able to eliminate the subsidiary from its financial statements and reduce its Brazilian exposure. He keeps a $15 price target and a Buy rating on the shares.
02/28/17
RHCO
02/28/17
NO CHANGE
RHCO
AES Corp. weakness overdone, says SunTrust
SunTrust analyst Ali Agha says that the 7% decline in AES' stock "was a significant overreaction to lower than expected 2017 guidance." The analyst says that the guidance miss was caused by one-time factors, and he thinks that the stock's valuation is attractive. Agha says that the shares have reached an attractive entry point, and he keeps a Buy rating on the shares.
01/04/17
RBCM
01/04/17
DOWNGRADE
RBCM
Sector Perform
AES Corp. downgraded on macro headwinds, possible project delays at RBC Capital
As noted earlier, RBC Capital downgraded AES Corp to Sector Perform from Outperform. As reasons for the downgrade, analyst Shelby Tucker cited macro headwinds, including the dollar's strength, and possible project delays identified by the company's management. Target to $12 from $13.
PRTY Party City
$13.95

1.75 (14.34%)

11/13/17
11/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Party City (PRTY) assumed with an Overweight at JPMorgan. 2. MongoDB (MDB) was initiated with a Buy at Stifel and Canaccord, an Overweight at Barclays, an Equal Weight at Morgan Stanley, a Market Perform at JMP Securities, and a Neutral at Goldman Sachs. 3. Arista Networks (ANET) initiated with a Neutral at Piper Jaffray. 4. NetScout (NTCT) initiated with an Overweight at Piper Jaffray. 5. Aveo Oncology (AVEO) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/13/17
JPMS
11/13/17
INITIATION
Target $14
JPMS
Overweight
Party City assumed with an Overweight at JPMorgan
JPMorgan analyst Tami Zakaria assumed coverage of Party City with an Overweight rating and $14 price target. The rating is unchanged and the price target is lowered from $18.
10/24/17
10/24/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Hasbro (HAS) upgraded to Overweight from Equal Weight at Barclays with analyst Felicia Hendrix saying she believes the 8.6% selloff in shares yesterday on news of the Toys R Us bankruptcy is overdone. 2. Party City (PRTY) upgraded to Outperform from Market Perform at BMO Capital with analyst Wayne Hood saying the 34% pullback in shares over the past 12 months creates a favorable risk/reward entry point. 3. Alon USA Partners (ALDW) upgraded to Outperform from Neutral at Macquarie. 4. EnLink Midstream (ENLC) upgraded to Buy from Neutral at UBS with analyst Shneur Gershuni saying the company's 16% interest in Oklahoma Tall Oak is underappreciated following the recent selloff in the shares. 5. Delek US (DK) upgraded to Outperform from Neutral at Macquarie. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/24/17
BMOC
10/24/17
UPGRADE
Target $16
BMOC
Outperform
Party City upgraded to Outperform from Market Perform at BMO Capital
BMO Capital analyst Wayne Hood upgraded Party City to Outperform saying the 34% pullback in shares over the past 12 months creates a favorable risk/reward entry point. Channel checks do not suggest comp-store sales below expectations nor unplanned promotions that would indicate broad weakness, Hood tells investors in a research note. The analyst has a $16 price target for the shares.

TODAY'S FREE FLY STORIES

FCX

Freeport McMoRan

$19.96

0.56 (2.89%)

21:10
01/21/18
01/21
21:10
01/21/18
21:10
Downgrade
Freeport McMoRan rating change at CIBC »

Freeport McMoRan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

DCM

NTT DoCoMo

$24.74

0.08 (0.32%)

21:09
01/21/18
01/21
21:09
01/21/18
21:09
Downgrade
NTT DoCoMo rating change at HSBC »

NTT DoCoMo downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HAL

Halliburton

$53.01

0.65 (1.24%)

, PETS

PetMed Express

$53.24

2.67 (5.28%)

20:25
01/21/18
01/21
20:25
01/21/18
20:25
Earnings
Notable companies reporting before Monday's open »

Notable companies…

HAL

Halliburton

$53.01

0.65 (1.24%)

PETS

PetMed Express

$53.24

2.67 (5.28%)

OPB

Opus Bank

$28.70

0.05 (0.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 22

    Jan

  • 22

    Jan

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

20:00
01/21/18
01/21
20:00
01/21/18
20:00
Hot Stocks
On The Fly: Top five weekend stock stories »

Catch up on the…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

SNE

Sony

$49.89

0.72 (1.46%)

BA

Boeing

$337.73

-2.43 (-0.71%)

WMT

Walmart

$104.59

0.29 (0.28%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 07

    Feb

  • 07

    Feb

  • 20

    Feb

  • 21

    Feb

  • 28

    Feb

  • 18

    Mar

XRX

Xerox

$31.80

0.43 (1.37%)

19:18
01/21/18
01/21
19:18
01/21/18
19:18
Periodicals
Icahn, Deason pushing for Xerox to explored sale, WSJ reports »

Carl Icahn and Darwin…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

18:22
01/21/18
01/21
18:22
01/21/18
18:22
Periodicals
Facebook to open three new digital training hubs in Europe, Reuters says »

Facebook said it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 28

    Feb

TWX

Time Warner

$93.36

0.39 (0.42%)

, CMCSA

Comcast

$42.50

0.65 (1.55%)

17:56
01/21/18
01/21
17:56
01/21/18
17:56
Hot Stocks
Box Office Battle: 'Jumanji' wins weekend with $20M »

Once again, Sony's…

TWX

Time Warner

$93.36

0.39 (0.42%)

CMCSA

Comcast

$42.50

0.65 (1.55%)

CMCSK

Comcast

SNE

Sony

$49.89

0.72 (1.46%)

FOX

21st Century Fox

$36.26

0.53 (1.48%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

LGF.A

Lionsgate

$35.42

0.92 (2.67%)

DIS

Disney

$110.59

0.17 (0.15%)

VIAB

Viacom

$33.36

-0.59 (-1.74%)

VIA

Viacom

$39.20

-0.5 (-1.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 24

    Jan

  • 06

    Feb

  • 07

    Feb

  • 07

    Feb

  • 08

    Feb

  • 08

    Feb

  • 08

    Feb

CTIC

CTI BioPharma

16:11
01/21/18
01/21
16:11
01/21/18
16:11
Conference/Events
CTI BioPharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

ZSAN

Zosano Pharma

$0.45

-0.0387 (-7.92%)

16:00
01/21/18
01/21
16:00
01/21/18
16:00
Conference/Events
Zosano Pharma to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SANM

Sanmina

$35.45

0.5 (1.43%)

15:39
01/21/18
01/21
15:39
01/21/18
15:39
Conference/Events
Sanmina to hold a conference call »

Management holds an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

12:05
01/21/18
01/21
12:05
01/21/18
12:05
Periodicals
Amazon automated grocery store opens Monday, Reuters says »

Amazon will open its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

  • 18

    Mar

TWTR

Twitter

$23.66

-0.38 (-1.58%)

09:07
01/21/18
01/21
09:07
01/21/18
09:07
Periodicals
Twitter COO in discussions to become SoFi CEO, WSJ reports »

Twitter's COO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

CLF

Cleveland-Cliffs

$8.49

0.08 (0.95%)

09:02
01/21/18
01/21
09:02
01/21/18
09:02
Hot Stocks
Cleveland-Cliffs addresses ''inaccurate media reports' on Nashwauk property »

Cleveland-Cliffs said it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

BMY

Bristol-Myers

$62.28

0.45 (0.73%)

15:26
01/20/18
01/20
15:26
01/20/18
15:26
Hot Stocks
Opdivo, Yervoy combo demonstrates activity in patients with dMMR, MSI-H mCRC »

Bristol-Myers Squibb…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 05

    Feb

  • 08

    Feb

  • 05

    Mar

  • 08

    Mar

EXEL

Exelixis

$28.00

0.14 (0.50%)

, RHHBY

Roche

$30.69

0.18 (0.59%)

15:22
01/20/18
01/20
15:22
01/20/18
15:22
Hot Stocks
Exelixis presents updated results from Phase 1b clinical trial in CRC »

Exelixis (EXEL) announced…

EXEL

Exelixis

$28.00

0.14 (0.50%)

RHHBY

Roche

$30.69

0.18 (0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 01

    Feb

  • 08

    Feb

  • 15

    Feb

  • 23

    Feb

ARRY

Array BioPharma

$13.14

0.26 (2.02%)

15:17
01/20/18
01/20
15:17
01/20/18
15:17
Hot Stocks
Array BioPharma updates results from BEACON Phase 3 trial »

Array BioPharma and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jun

  • 30

    Jun

SO

Southern Company

$44.44

-0.46 (-1.02%)

15:13
01/20/18
01/20
15:13
01/20/18
15:13
Hot Stocks
Southern Company accelerates restoration efforts in Puerto Rico »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$29.43

0.19 (0.65%)

15:10
01/20/18
01/20
15:10
01/20/18
15:10
Hot Stocks
Teck Resources announces Elkview incident »

Teck Resources announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Feb

TWTR

Twitter

$23.66

-0.38 (-1.58%)

14:03
01/20/18
01/20
14:03
01/20/18
14:03
Hot Stocks
Twitter begins notifying users exposed to Russian propaganda during elections »

Twitter, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 07

    Feb

  • 08

    Feb

  • 28

    Feb

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

, SPX

S&P 500

13:58
01/20/18
01/20
13:58
01/20/18
13:58
Periodicals
Government shuts down on anniversary of Trump presidency, Reuters reports »

President's Trump…

SPY

SPDR S&P 500 ETF Trust

$280.41

1.27 (0.45%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.29

1.49 (0.83%)

, NYT

New York Times

$21.90

1.7 (8.42%)

13:48
01/20/18
01/20
13:48
01/20/18
13:48
Periodicals
NY Times stock jumps after Facebook's announcement, Recode reports »

Facebook (FB) CEO Mark…

FB

Facebook

$181.29

1.49 (0.83%)

NYT

New York Times

$21.90

1.7 (8.42%)

NWSA

News Corp.

$17.22

0.21 (1.23%)

FOXA

21st Century Fox

$36.65

0.47 (1.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 07

    Feb

  • 07

    Feb

  • 28

    Feb

WMT

Walmart

$104.59

0.29 (0.28%)

13:36
01/20/18
01/20
13:36
01/20/18
13:36
Periodicals
Still time to shop Walmart shares as company makes changes, Barron's says »

In a follow-up story,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, NFLX

Netflix

$220.46

0.13 (0.06%)

08:59
01/20/18
01/20
08:59
01/20/18
08:59
Periodicals
Netflix among likely candidates for an Apple purchase, Barron's says »

Especially for tech…

AAPL

Apple

$178.46

-0.8 (-0.45%)

NFLX

Netflix

$220.46

0.13 (0.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 30

    Jan

  • 01

    Feb

BA

Boeing

$337.73

-2.43 (-0.71%)

08:50
01/20/18
01/20
08:50
01/20/18
08:50
Periodicals
Boeing not a sell just yet, Barron's says »

Boeing stock has come…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jan

  • 21

    Feb

AAPL

Apple

$178.46

-0.8 (-0.45%)

, EADSY

Airbus

$28.43

0.755 (2.73%)

08:24
01/20/18
01/20
08:24
01/20/18
08:24
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$178.46

-0.8 (-0.45%)

EADSY

Airbus

$28.43

0.755 (2.73%)

BA

Boeing

$337.73

-2.43 (-0.71%)

VZ

Verizon

$51.91

0.36 (0.70%)

NYT

New York Times

$21.90

1.7 (8.42%)

TWX

Time Warner

$93.36

0.39 (0.42%)

DIS

Disney

$110.59

0.17 (0.15%)

TIME

Time Inc.

$18.55

0.05 (0.27%)

AMZN

Amazon.com

$1,294.58

1.26 (0.10%)

BAC

Bank of America

$31.72

0.24 (0.76%)

GS

Goldman Sachs

$256.12

5.15 (2.05%)

BK

BNY Mellon

$56.61

1.26 (2.28%)

WLKP

Westlake Chemical Partners

$24.45

-0.1 (-0.41%)

MON

Monsanto

$120.66

1.8 (1.51%)

DLTR

Dollar Tree

$114.73

1.83 (1.62%)

CE

Celanese

$112.96

1.93 (1.74%)

LYB

LyondellBasell

$119.92

3.03 (2.59%)

TSE

Trinseo

$79.45

2.2 (2.85%)

EYE

National Vision

$43.13

1.12 (2.67%)

ETFC

E-Trade

$54.28

0.63 (1.17%)

LPLA

LPL Financial

$59.03

0.53 (0.91%)

AMTD

TD Ameritrade

$55.17

0.21 (0.38%)

SCHW

Charles Schwab

$55.48

0.15 (0.27%)

ADS

Alliance Data

$261.82

5.88 (2.30%)

FISV

Fiserv

$138.11

0.17 (0.12%)

FLT

FleetCor

$206.65

3.4 (1.67%)

HAWK

Blackhawk

$45.25

0.1 (0.22%)

MTZ

MasTec

$53.30

1.25 (2.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

  • 25

    Jan

  • 25

    Jan

  • 26

    Jan

  • 31

    Jan

  • 31

    Jan

  • 31

    Jan

  • 01

    Feb

  • 01

    Feb

  • 01

    Feb

  • 02

    Feb

  • 06

    Feb

  • 07

    Feb

  • 15

    Feb

  • 16

    Feb

  • 21

    Feb

  • 08

    Mar

  • 18

    Mar

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.